Pfizer Inc. (NYSE:PFE) insider Douglas M. Lankler sold 50,000 shares of the stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $36.89, for a total transaction of $1,844,500.00. Following the completion of the sale, the insider now owns 133,057 shares in the company, valued at approximately $4,908,472.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Pfizer Inc. (PFE) traded down $0.41 during midday trading on Wednesday, reaching $36.35. 22,180,000 shares of the company were exchanged, compared to its average volume of 28,010,000. Pfizer Inc. has a 12-month low of $31.67 and a 12-month high of $39.43. The stock has a market capitalization of $216,390.00, a P/E ratio of 20.77, a PEG ratio of 2.06 and a beta of 0.91. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.35 and a quick ratio of 1.10.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The firm had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. During the same period in the prior year, the firm posted $0.47 earnings per share. The firm’s quarterly revenue was up .6% compared to the same quarter last year. equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer declared that its board has initiated a stock buyback plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.
A number of analysts have recently weighed in on PFE shares. UBS Group set a $40.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Sanford C. Bernstein set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a research note on Wednesday, January 17th. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price objective on the stock in a research note on Thursday, November 23rd. Finally, Morgan Stanley set a $41.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Friday, January 5th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and a consensus target price of $39.40.
Institutional investors and hedge funds have recently bought and sold shares of the business. Mckinley Capital Management LLC Delaware purchased a new position in Pfizer during the second quarter valued at $103,000. Earnest Partners LLC purchased a new position in Pfizer during the fourth quarter valued at $105,000. First Dallas Securities Inc. purchased a new position in Pfizer during the fourth quarter valued at $118,000. Woodard & Co. Asset Management Group Inc. ADV purchased a new position in Pfizer during the fourth quarter valued at $118,000. Finally, Herndon Capital Management LLC purchased a new position in Pfizer during the second quarter valued at $120,000. 71.41% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/03/14/insider-selling-pfizer-inc-pfe-insider-sells-50000-shares-of-stock.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.